Oncimmune has announced two separate substantial agreements with Roche and CedarsSinai to use the newly developed Infectious Disease panel to provide antibody and autoantibody profiling. Both agreements are with existing customers and highlight a deepening relationship with partners. In particular, it shows that value Roche see in the service with Roche now using the service across oncology, autoimmune (Genentech) and infectious disease areas. The announcement also adds continued support for the ....
06 Apr 2021
Two ImmunoINSIGHTS contract for COVID-19 panel
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Two ImmunoINSIGHTS contract for COVID-19 panel
Oncimmune Holdings Plc (ONC:LON) | 26.4 0 0.0% | Mkt Cap: 19.6m
- Published:
06 Apr 2021 -
Author:
Edward Thomason -
Pages:
3
Oncimmune has announced two separate substantial agreements with Roche and CedarsSinai to use the newly developed Infectious Disease panel to provide antibody and autoantibody profiling. Both agreements are with existing customers and highlight a deepening relationship with partners. In particular, it shows that value Roche see in the service with Roche now using the service across oncology, autoimmune (Genentech) and infectious disease areas. The announcement also adds continued support for the ....